Desvenlafaxine Extended-Release Tablets Articles
Research results for Pfizer's Chantix, Pristiq and Toviaz
27 January 2013
Pfizer to face class action over alleged securities fraud by Wyeth
19 September 2012
Watson challenges Pfizer's Pristiq patent
26 June 2012
Impax now to co-promote Pfizer’s Lyrica; updates on APEX-PD trial; Pfizer in deal with Stemgent on reagents
16 April 2010
Impax to co-promote Wyeth's Pristiq
30 March 2009
Thomson releases Pharma Matters reports for 1st qtr
1 September 2008
US FDA set for even fewer approvals in 2008
1 September 2008
Wyeth debuts Pristiq in US pharmacies
19 May 2008
Wyeth's Pristiq cleared for adults with MDD
10 March 2008
New head of Wyeth France to manage future growth
29 October 2007
Pfizer-Wyeth merger speculation fuels debate
3 September 2007
Stock Commentary - New York week to Aug 13, 2007
20 August 2007
Stock Commentary - New York week to July 30, 2007
6 August 2007
Tentative FDA OK for second Pristiq indication
30 July 2007
Wyeth's Pristiq extends relapse time in MDD
4 June 2007
Wyeth's 1st-qtr income up 12% to $1.25B
30 April 2007
Wyeth gets tentative US approval for Pristiq
29 January 2007
Wyeth's income climbs 33% to $1.16B in 3rd-qtr, on continued success of Enbrel and Prevnar
30 October 2006
Wyeth unveils seven late-stage drugs for 11 indications at its annual R&D presentation
16 October 2006
Showing 1-23 of 23 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
